ITCI Price Prediction Next Week
ITCI Stock Price Prediction and Recommendation
Technical Analysis:
- RSI (14): 87.90 (Overbought zone, suggesting potential pullback)
- MACD: Positive but with decreasing histogram, indicating weakening upward momentum
- Fibonacci Levels: Resistance at 131.01, Support at 128.47
News Impact:
- JNJ Discontinues Aticaprant Development: Positive for ITCI as it reduces competition in the depression treatment market.
- JNJ's Acquisition of ITCI: Mixed implications; potential for increased resources but possible integration challenges.
Price Action:
- Current Price: 129.3 (pre-market drop of 1.48%)
- Target Support: 128.47 (Fibonacci support level)
Recommendation:
Sell ITCI as it approaches resistance, targeting the support level for a short-term gain.
ITCI Similar Chart Price Prediction
The price of ITCI is predicted to go up -8.67%, based on the high correlation periods with QIPT. The similarity of these two price pattern on the periods is 99.11%.
ITCI
QIPT
Down: -8.67%Similarity: 99.11%
ITCI Revenue Forecast
ITCI EPS Forecast
ITCI FAQs
What is ITCI revenue forecast for next quarter？
ITCI Analyst's Forecast
Graig Suvannavejh
Mizuho
Buy → Hold
2025-02-24
Price Target
$140 → $132
Upside
+2.67%
Mizuho analyst Graig Suvannavejh downgraded Intra-Cellular (ITCI) to Neutral from Outperform with a price target of $132, down from $140, after Johnson & Johnson (JNJ) agreed to acquire all of the company's outstanding shares for $132 in cash. The firm sees no reason for the pending takeover deal to get blocked, especially in light of recent precedent transactions. In addition, another bidder is unlikely to emerge at this point, the analyst tells investors in a research note.
Sumant Kulkarni
Canaccord Genuity
Strong Buy → Hold
2025-01-31
Price Target
$119 → $132
Upside
+3.87%
Brian Abrahams
RBC Capital
Buy → Hold
2025-01-22
Price Target
$108 → $132
Upside
+3.81%
